Learning objectives At the end of this section you will: Have applied the knowledge gained from the earlier sessions to: Understand the impact of pulsatile.

Slides:



Advertisements
Similar presentations
Pharmacological Management of Parkinson’s Disease
Advertisements

Parkinsons Disease Management in Primary Care. Introduction Progressive condition 1:500 whole population 1:50 of elderly 1:10 Nursing Home Residents.
+ The Power of Music: “music therapy and the brain” Lewelyn Fernandez University of California Merced.
‘Adjusting to Life Events and Their Impact on Mental Health.’
Parkinson’s Finding the cure Presentation
Diagnosis and Management of Parkinson’s Disease
The PARticulars of Parkinson’s Disease
Considering the pre-clinical and clinical evidence for continuous dopaminergic stimulation (CDS) This educational material has been supported by Abbott.
The Right Prescription A Call to Action for junior doctors on the use of antipsychotic drugs for people with dementia.
RNFL Thickness. The ubiquitin proteasome pathway – PD genes Adapted from Eriksen et al Arch Neurol 2005, 6:
Initial Diagnosis and Management of Parkinson’s Disease
Describe and Evaluate the Cognitive Treatment for Schizophrenia
Depressive Disorders.
Specialist Physical & Mental Health Private Rehabilitation Services.
Parkinson’s Disease and Treatment Shalla Hanson Medicinal Chemistry April 2009.
Evidence-based review of current Parkinson’s disease treatments This educational material has been supported by Abbott.
Parkinson ’ s disease. Function Anatomy of Parkinson ’ s Disease.
Chapter 30 Agents Used to Treat Parkinson’s Disease.
Treatment of Parkinson’s Disease Dementia (PDD) Shanil Ebrahim.
Duodenal Levodopa Treatment in advanced Parkinson’s Disease
Non-motor symptoms of Parkinson’s disease This educational material has been supported by Abbott.
Treatment of Parkinson’s Disease Thomas L. Davis, M.D. Associate Professor of Neurology Vanderbilt School of Medicine.
Alzheimer’s Disease The most common cause of Dementia –Progressive Memory Loss Plus loss in one other area of cognition: Perception Attention Language/Symbols.
Surgery for Parkinson’s Disease: Focus on Deep Brain Stimulation Ramón L Rodríguez, MD Director of Clinical Services University of Florida Movement Disorders.
BY: MACKENZIE SOARES ALYSSA MEDIEROS STEPHANIE GARDNER Parkinson's Disease.
Adult Medical-Surgical Nursing Neurology Module: Parkinson’s Disease.
Treatment of Parkinson Disease David Tran, 2013 Mercer University PharmD Candidate.
Benjamin L. Walter M.D. Medical Director, Deep Brain Stimulation Program Neurological Institute University Hospitals Case Medical Center Management of.
Cause Of Mental Disorders Destiny Carter Period 3.
OLD AGE PSYCHIATRY FOR PRIMARY CARE VOCATIONAL TRAINEES Dr Nick Pearson Consultant in the Psychiatry of Old Age Reading
Treatment Options in Poland Rafał Żukowski Association „Integration”, Warsaw, Poland Gamian Regional Seminar, Bucharest, 23 th May, 2009.
The evolution of non-motor symptoms in patients with Parkinson’s disease treated with Duodopa intestinal gel Natalia Pritcan Doctor Jozsef Attila Szasz.
Issues to be addressed Is BPSD one entity? Is BPSD part of the diagnosis of dementia? Are BPSD symptoms which cut across diagnoses? Which syndromes have.
GERIATRIC EDUCATION SERIES Presented in partnership by Funded in part by a grant from the EJC Foundation.
Schizophrenia is a long term mental disorder of a type involving a break down, in a relation between thought, emotion, and behaviour, leading to faulty.
Treatment of Parkinson‘s Disease in the Advanced Stage
Isolation and emotional wellbeing Dr James Warner CNWL Foundation Trust.
Drugs in parkinsonism ilos
Parkinson’s Disease Angela Duncan June Why I Chose This Subject Common neurodegenerative disorder / in Scotland Expected increase.
Drugs Used for Parkinson’s Disease Chapter 15 Mosby items and derived items © 2010, 2007, 2004 by Mosby, Inc., an affiliate of Elsevier Inc.
LO: To be able to describe and evaluate the Cognitive Treatment for Schizophrenia.
Psychosis Case # year old white male presents to the emergency room with his new college roommates. He will only say he can’t sleep because the.
Management of Parkinson’s disease (in the acute medical ward) C. M. James MD FRCP FAcadMEd Consultant Physician Withybush Hospital, Pembrokeshire.
Memory and Aging Educational Presentation Presented by Tessa Lundquist, M.S. University of Massachusetts Amherst.
When the going gets tough…. How to select patients with Parkinson’s disease for advanced therapies Dr Paul Worth PhD FRCP Consultant Neurologist, Addenbrooke’s.
Understanding Parkinsons Disease
Impulse Control Disorders (ICD) and Parkinson Disease (PD)
Involuntary movements in Parkinson’s disease: not always what it seems
Understanding Your Role
By: Johanna Miner, Kendra Hobbs and Ainsley MAcDonald
24 hour levodopa-carbidopa intestinal gel may reduce “unresponsive” freezing of gait and falls in Parkinson’s disease Florence CF Chang, David S Tsui,
Expert Perspectives on New Treatment Options for Parkinson Disease Psychosis.
Dementia and Parkinson’s ADHD
The Relationship Between Mental and Physical Health
SEXUAL DYSFUNCTION IN PARKINSON'S DISEASE. In people with Parkinson’s disease (PD), sexual dysfunction is a common complaint with many research studies.
What is Dementia? A term that describes a wide range of symptoms associated with a decline in memory or other thinking skills. Dementia may be severe.
Motor Fluctuations in Parkinson Disease: Options and Strategies
A 52-year-old woman with abnormal eye movements
Parkinson Disease:.
Copyright © 2004 American Medical Association. All rights reserved.
Describe and Evaluate the Cognitive Treatment for Schizophrenia
Compulsive Self-pleasuring? Could Be Pramipexole.
Clinical Recognition and Treatment of Levodopa-Induced Dyskinesia
Pharmacological Management of Parkinson’s Disease
Advanced Parkinson Disease: Are We Breaking New Ground?
Management in Primary Care
Parkinson’s Disease Definitions Disease features Pathology
Motor Fluctuations in PD
Evidence-based review of current Parkinson’s disease treatments
Women and Parkinson’s Disease
Presentation transcript:

Learning objectives At the end of this section you will: Have applied the knowledge gained from the earlier sessions to: Understand the impact of pulsatile dopaminergic therapy-induced motor complications on patient functioning Identify which patient types could benefit from the three CDS treatments currently available

Diagnosed 1986 His life revolved around taking tablets Problems with sleep, which had an impact on his quality of life In 1999, he received carbidopa/levodopa infusion for the first time A PEG operation was performed in May 2000 Case study 1 Patient history

Q. What additional options are available to further improve the quality of life of this patient? Discussion

Results Since 2002, 24-hour infusion has improved his sleep Few drawbacks From having a life dominated by tablet-taking, increasingly severe motor functions and very poor sleep, patient feels that he can once again fill his time with meaningful activities At the latest follow-up, he described his motor functions and sleep as good

CDS impact on sleep Adapted from Nyholm et al. Neurology 2005;65: hour infusion – impact on sleep (N=1; PD sleep scale; maximum 150; HY stage 4-5:~90)

‘On/off’ mobility chart Anders. Data on file On/Off mobility chart: conventional treatment versus intraduodenal carbidopa/levodopa gel infusion Intraduodenal carbidopa/levodopa gel infusion

Conclusions DBS not suitable due to previous depression Without pump therapy living alone would not have been possible Living alone is possible with intraduodenal carbidopa/levodopa gel infusion in some cases 24-hour infusion of great benefit for this patient

Case study 2 Patient history Male, 58 years old Occupation: teacher Parkinson‘s disease since the age of 45, otherwise healthy Motor fluctuations and dyskinesias since the age of 52

Patient history Symptoms and treatment 2005 ‘On-off‘ fluctuations; severe ‘off’ phases with freezing; ‘on’ phases with pronounced dyskinesias Depressive symptoms No dementia Medication: –Pramipexole 1.4 mg daily –Levodopa 525 mg daily –Entacapone 1400 mg daily –Amantadine 200 mg daily –Quetiapine 50 mg daily

Patient history Symptoms and behaviour Dopamine dysregulation syndrome (DDS) Went to several doctors for prescriptions Consumed up to 3 g of levodopa daily Did not follow advice to restrict medication at all Punding Impulse control disorder (ICD) Hypersexuality –Called sex hotlines –Visited prostitutes daily Gambling –Lost large parts of personal savings Dopaminergic psychotic symptoms Hallucinations Confusion

Patient history Consequences of actions Lost family, home Legal guardian necessary to control his economy Nursing home

Treatment Step 1 Levodopa monotherapy 800 mg daily Result: –Psychotic symptoms improved, but did not disappear –DDS and ICD did not change –Motor fluctuations and dyskinesias worsened

Treatment Step 2 Quetiapine raised to 200 mg daily Result –DDS and ICD did not change

Q. Considering the results from treatment step 2, which treatment option would be appropriate for the next treatment step: DBS? Subcutaneous apomorphine infusion? Intraduodenal carbidopa/levodopa gel infusion? Other? Discussion

Treatment Step 3 Treatment: Intraduodenal carbidopa/levodopa gel infusion 5.2 ml/h daytime, 3.6 ml/h night-time, bolus: 2 ml, max 5 per day Quetiapine 75 mg daily All other medication stopped Result: DDS resolved almost completely ICD resolved completely No psychotic symptoms, no confusion Cognitive functions normal Strong improvement of motor fluctuations Side effects: Percutaneous endoscopic jejunostomy (PEJ) problems x 2, replaced

Q. In your opinion, what was the underlying reason for the improvements observed with intraduodenal carbidopa/levodopa gel infusion? Discussion